Rocket Pharmaceuticals (RCKT) Other financing activities (2015 - 2024)

Rocket Pharmaceuticals (RCKT) has 8 years of Other financing activities data on file, last reported at $321000.0 in Q4 2024.

• For the quarter ending Q4 2024, Other financing activities fell 85.57% year-over-year to $321000.0; the trailing twelve-month figure through Sep 2025 stood at $321000.0 (down 93.72% YoY), and the FY2024 full-year result was $3.2 million, up 43.93% from the prior year.
• Other financing activities advanced to $321000.0 in Q4 2024, from $176000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $280.8 million in Q4 2020 to a low of -$10.2 million in Q4 2021.
• A 5-year average of $19.1 million and a median of $631000.0 in 2022 frame the typical range for Other financing activities.
• Peak annual rise in Other financing activities reached 37066.67% in 2021, while the deepest fall reached 103.63% in 2021.
• Tracing RCKT's Other financing activities over 5 years: stood at $280.8 million in 2020, then sank by 103.63% to -$10.2 million in 2021, then soared by 106.19% to $631000.0 in 2022, then soared by 252.46% to $2.2 million in 2023, then slumped by 85.57% to $321000.0 in 2024.
• Business Quant data shows RCKT's Other financing activities at $321000.0 in Q4 2024, $176000.0 in Q3 2024, and $1.5 million in Q2 2024.